Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical, has granted Cipla exclusive development and commercialisation rights to rolditamig deuderuxtecan (TQB2102), a proprietary HER2 bispecific ADC dual-targeting HER2 ECD II and ECD IV with a cleavable linker and topoisomerase I inhibitor payload, across India, South Africa, and five other high-growth emerging markets. Cipla runs local clinical development, filing, and commercialisation, while Chia Tai Tianqing supplies product; Sino Biopharma receives upfront and milestone payments up to USD 123 million plus double-digit tiered royalties, taking cumulative TQB2102 regional-deal cash to about USD 30 million across two partnerships.

TQB2102 holds three China CDE breakthrough therapy designations and is in multiple Phase III studies spanning HER2-low breast, HER2-positive breast, colorectal, and biliary cancers, with a Phase Ib ORR of 53.4% in heavily pretreated HER2-low breast patients and only 0.55% grade 2 interstitial lung disease.